DECATUR MEMORIAL HOSPITAL
- Type
- Teaching hospital
- Where
- DECATUR, IL
- Medicare CCN
- 140135
- Received
- $610,325 in 72 records, 2019 ($2,292 general, $608,033 research)
- Source
- CMS Open Payments search ↗
On this site
- Nonprofit contractor: DECATUR MEMORIAL HOSPITAL Fuzzy (name and state)
- Plan sponsor: DECATUR MEMORIAL HOSPITAL Fuzzy (name and state)
- Federal award recipient: DECATUR MEMORIAL HOSPITAL Fuzzy (name and state)
- Nonprofit: DECATUR MEMORIAL HOSPITAL Fuzzy (name and state)
- Trademark owner: Decatur Memorial Hospital Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2019 | General payment | 3 | $2,292 |
| 2019 | Research payment | 69 | $608,033 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Amgen Inc. | 2 | $389,995 | 2019 |
| AstraZeneca UK Limited | 5 | $79,137 | 2019 |
| AstraZeneca Pharmaceuticals LP | 4 | $45,316 | 2019 |
| Merck Sharp & Dohme LLC | 49 | $34,567 | 2019 |
| SEAGEN INC. | 2 | $32,013 | 2019 |
| PUMA BIOTECHNOLOGY, INC. | 3 | $16,481 | 2019 |
| Radius Health, Inc. | 1 | $8,165 | 2019 |
| Medline Industries LP | 1 | $1,500 | 2019 |
| SANOFI US SERVICES INC. | 1 | $1,250 | 2019 |
| Incyte Corporation | 1 | $958 | 2019 |
| Linvatec Corporation | 1 | $742 | 2019 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $150 | 2019 |
| Abbott Laboratories | 1 | $50 | 2019 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 69 | $608,033 |
| Charitable Contribution | 1 | $1,500 |
| Grant | 1 | $742 |
| Space rental or facility fees (teaching hospital only) | 1 | $50 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2019-12-31 | Linvatec Corporation | $742 | Grant | In-kind items and services | SHOULDER MANUAL INSTRUMENTS Device, ORTHOPEDIC SURGERY | 2019 | |
| 2019-12-31 | AstraZeneca UK Limited | $37 | Research payment | In-kind items and services | IMFINZI Drug, Oncology | A Phase II, Multi-Center, Single-Arm, Global Study of MEDI4736 Monotherapy in Patients With Recurrent or Metastatic Squa | 2019 |
| 2019-12-31 | AstraZeneca UK Limited | $23 | Research payment | In-kind items and services | IMFINZI Drug, Oncology | A Phase II Randomized Open Label Multi Center Global Study of MEDI4736 Monotherapy Tremelimumab Monotherapy and MEDI4736 | 2019 |
| 2019-12-02 | Merck Sharp & Dohme LLC | $60 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2019 |
| 2019-11-21 | Merck Sharp & Dohme LLC | $60 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2019 |
| 2019-11-21 | Merck Sharp & Dohme LLC | $30 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2019 |
| 2019-11-19 | Radius Health, Inc. | $8,165 | Research payment | Cash or cash equivalent | A RANDOMIZED, MULTICENTER, PHASE 2 STUDY OF ELACESTRANT RAD1901 VERSUS INVESTIGATOR'S CHOICE OF FULVESTRANT OR AROMATASE | 2019 | |
| 2019-11-18 | Merck Sharp & Dohme LLC | $41 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2019 |
| 2019-11-15 | Merck Sharp & Dohme LLC | $30 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2019 |
| 2019-11-13 | Merck Sharp & Dohme LLC | $97 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine,Cisplatin versus Placebo Plus Gemcitabine,Cis | 2019 |
| 2019-11-13 | Merck Sharp & Dohme LLC | $97 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine,Cisplatin versus Placebo Plus Gemcitabine,Cis | 2019 |
| 2019-11-05 | Merck Sharp & Dohme LLC | $16 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine,Cisplatin versus Placebo Plus Gemcitabine,Cis | 2019 |
| 2019-11-05 | Merck Sharp & Dohme LLC | $16 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine,Cisplatin versus Placebo Plus Gemcitabine,Cis | 2019 |
| 2019-11-04 | Merck Sharp & Dohme LLC | $165 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine,Cisplatin versus Placebo Plus Gemcitabine,Cis | 2019 |
| 2019-11-04 | Merck Sharp & Dohme LLC | $165 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine,Cisplatin versus Placebo Plus Gemcitabine,Cis | 2019 |
| 2019-10-22 | Merck Sharp & Dohme LLC | $60 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2019 |
| 2019-10-22 | Merck Sharp & Dohme LLC | $30 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2019 |
| 2019-10-21 | SEAGEN INC. | $20,263 | Research payment | Cash or cash equivalent | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin ASG-22CE in Combination With Pembrolizumab andor Chemot | 2019 | |
| 2019-10-16 | Merck Sharp & Dohme LLC | $21,652 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine,Cisplatin versus Placebo Plus Gemcitabine,Cis | 2019 |
| 2019-10-08 | AstraZeneca Pharmaceuticals LP | $9,318 | Research payment | Cash or cash equivalent | IMFINZI Drug, Oncology | A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Ste | 2019 |
| 2019-10-04 | Merck Sharp & Dohme LLC | $5,500 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine,Cisplatin versus Placebo Plus Gemcitabine,Cis | 2019 |
| 2019-09-18 | Merck Sharp & Dohme LLC | $96 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2019 |
| 2019-09-17 | Merck Sharp & Dohme LLC | $1,400 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine,Cisplatin versus Placebo Plus Gemcitabine,Cis | 2019 |
| 2019-09-13 | Bayer Healthcare Pharmaceuticals Inc. | $150 | Research payment | Cash or cash equivalent | Stivarga Drug, Oncology | Clinical Study Site Agreement | 2019 |
| 2019-09-04 | Merck Sharp & Dohme LLC | $50 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2019 |
| 2019-08-22 | Merck Sharp & Dohme LLC | $50 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2019 |
| 2019-08-22 | Merck Sharp & Dohme LLC | $41 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2019 |
| 2019-07-15 | Merck Sharp & Dohme LLC | $50 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2019 |
| 2019-07-15 | Merck Sharp & Dohme LLC | $41 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2019 |
| 2019-07-03 | PUMA BIOTECHNOLOGY, INC. | $6,731 | Research payment | Cash or cash equivalent | Nerlynx Drug, Oncology | An Open?Label Study to Characterize the Incidence and Severity of Diarrhea | 2019 |
| 2019-06-27 | Medline Industries LP | $1,500 | Charitable Contribution | Cash or cash equivalent | 2019 | ||
| 2019-06-11 | Merck Sharp & Dohme LLC | $50 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2019 |
| 2019-06-10 | Merck Sharp & Dohme LLC | $50 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2019 |
| 2019-06-03 | Merck Sharp & Dohme LLC | $500 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2019 |
| 2019-05-31 | Abbott Laboratories | $50 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | FreeStyle Lite system Device, Diabetes Care | 2019 | |
| 2019-05-24 | AstraZeneca Pharmaceuticals LP | $2,050 | Research payment | Cash or cash equivalent | A Phase II Study of the Dual Immune Checkpoint Blockade with Durvalumab plus Tremelimumab Following Palliative Hypofract | 2019 | |
| 2019-05-24 | Merck Sharp & Dohme LLC | $500 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2019 |
| 2019-05-16 | PUMA BIOTECHNOLOGY, INC. | $7,500 | Research payment | Cash or cash equivalent | Nerlynx Drug, Oncology | A Randomized, Double-Blind, Placebo-Controlled Trial Of Neratinib | 2019 |
| 2019-05-14 | Merck Sharp & Dohme LLC | $500 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2019 |
| 2019-05-04 | Merck Sharp & Dohme LLC | $500 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2019 |
| 2019-05-01 | SEAGEN INC. | $11,750 | Research payment | Cash or cash equivalent | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin ASG-22CE in Combination With Pembrolizumab andor Chemot | 2019 | |
| 2019-04-29 | Merck Sharp & Dohme LLC | $50 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2019 |
| 2019-04-26 | Merck Sharp & Dohme LLC | $100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2019 |
| 2019-04-24 | Merck Sharp & Dohme LLC | $50 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2019 |
| 2019-04-12 | PUMA BIOTECHNOLOGY, INC. | $2,250 | Research payment | Cash or cash equivalent | Nerlynx Drug, Oncology | An Open?Label Study to Characterize the Incidence and Severity of Diarrhea | 2019 |
| 2019-04-04 | Merck Sharp & Dohme LLC | $100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2019 |
| 2019-04-03 | Merck Sharp & Dohme LLC | $50 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2019 |
| 2019-04-03 | Merck Sharp & Dohme LLC | $41 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2019 |
| 2019-04-02 | Merck Sharp & Dohme LLC | $50 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2019 |
| 2019-04-01 | SANOFI US SERVICES INC. | $1,250 | Research payment | Cash or cash equivalent | ISATUXIMAB Drug | A Phase 1b Study of SAR650984 (Anti-CD38 mAb) in Combination with Pomalidomide and Dexamethasone for the Treatment of Re | 2019 |
| 2019-03-25 | Merck Sharp & Dohme LLC | $100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2019 |
| 2019-03-19 | Merck Sharp & Dohme LLC | $100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2019 |
| 2019-03-11 | Merck Sharp & Dohme LLC | $100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2019 |
| 2019-03-11 | Merck Sharp & Dohme LLC | $50 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2019 |
| 2019-03-11 | Merck Sharp & Dohme LLC | $41 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2019 |
| 2019-03-08 | Merck Sharp & Dohme LLC | $50 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2019 |
| 2019-03-08 | Merck Sharp & Dohme LLC | $41 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2019 |
| 2019-02-28 | Merck Sharp & Dohme LLC | $100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2019 |
| 2019-02-13 | Merck Sharp & Dohme LLC | $500 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2019 |
| 2019-02-12 | AstraZeneca UK Limited | $77,580 | Research payment | Cash or cash equivalent | iMED Oncology project- Sarah Cannon Research Institute Agreemet | 2019 | |
| 2019-02-11 | Merck Sharp & Dohme LLC | $500 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2019 |
| 2019-02-05 | Incyte Corporation | $958 | Research payment | Cash or cash equivalent | PROSPECTIVE, NON INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED | 2019 | |
| 2019-01-28 | AstraZeneca UK Limited | $748 | Research payment | Cash or cash equivalent | IMFINZI Drug, Oncology | A Phase II Randomized Open Label Multi Center Global Study of MEDI4736 Monotherapy Tremelimumab Monotherapy and MEDI4736 | 2019 |
| 2019-01-28 | Merck Sharp & Dohme LLC | $500 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2019 |
| 2019-01-25 | Merck Sharp & Dohme LLC | $100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2019 |
| 2019-01-24 | Merck Sharp & Dohme LLC | $50 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2019 |
| 2019-01-24 | Merck Sharp & Dohme LLC | $41 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2019 |
| 2019-01-22 | Amgen Inc. | $278,568 | Research payment | In-kind items and services | Kyprolis Biological, Oncology | [ECOG] Randomized Phase III Trial of Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide a | 2019 |
| 2019-01-16 | Amgen Inc. | $111,427 | Research payment | In-kind items and services | Kyprolis Biological, Oncology | [ECOG] Randomized Phase III Trial of Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide a | 2019 |
| 2019-01-11 | AstraZeneca Pharmaceuticals LP | $28,275 | Research payment | Cash or cash equivalent | A Phase II Study to Assess the Activity of PD-L1 Inhibition with Durvalumab after Chemo-Radiotherapy in Patients with St | 2019 | |
| 2019-01-07 | AstraZeneca UK Limited | $748 | Research payment | Cash or cash equivalent | IMFINZI Drug, Oncology | A Phase II, Multi-Center, Single-Arm, Global Study of MEDI4736 Monotherapy in Patients With Recurrent or Metastatic Squa | 2019 |
| 2019-01-01 | AstraZeneca Pharmaceuticals LP | $5,673 | Research payment | Cash or cash equivalent | FASLODEX Drug, Oncology | SWOG S1222 Collaborative Post AI Study | 2019 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Decatur, IL, county Macon County, IL, state Illinois; placed by its city name.
| Measure | Place (city or town) Decatur, IL | County Macon County, IL | State Illinois |
|---|---|---|---|
| Population B01003 | 69,815 | 101,849 | 12,694,798 |
| Population, 2020 census P1 | 70,522 | 103,998 | 12,812,508 |
| Median age B01002 | 39.2 | 40.6 | 39.0 |
| Under 18 B01001 | 21.0% | 22.6% | 21.8% |
| 65 and over B01001 | 21.3% | 21.0% | 17.0% |
| Households B11001 | 30,920 | 43,468 | 5,036,449 |
| Foreign born B05002 | 3.1% | 2.7% | 14.7% |
| Median household income B19013 | $51,592 | $62,666 | $83,390 |
| Median family income B19113 | $74,623 | $86,291 | $106,018 |
| Per capita income B19301 | $32,769 | $36,605 | $46,406 |
| Poverty rate B17001 | 19.4% | 15.0% | 11.8% |
| Unemployment rate B23025 | 8.3% | 6.8% | 5.8% |
| Civilian labor force B23025 | 31,960 | 47,235 | 6,652,134 |
| Mean commute (minutes) B08013 | 17.7 | 19.4 | 27.8 |
| Bachelor's degree or higher B15003 | 21.6% | 24.4% | 37.8% |
| Housing units B25001 | 36,018 | 49,630 | 5,457,452 |
| Owner-occupied B25003 | 62.9% | 70.2% | 67.1% |
| Renters B25003 | 37.1% | 29.8% | 32.9% |
| Median home value B25077 | $99,600 | $127,300 | $263,300 |
| Median gross rent B25064 | $845 | $847 | $1,274 |
| White, not Hispanic B03002 | 64.9% | 73.3% | 58.1% |
| Black B03002 | 23.3% | 16.2% | 13.3% |
| Hispanic or Latino B03002 | 3.3% | 2.9% | 18.8% |
| Asian B03002 | 1.5% | 1.5% | 5.9% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.1% |
Economy now FRED unemployment 4.6% in Sep 2026 (4.5% a year earlier); per capita personal income $78,987 in 2025, up 28% in five years (+3.1% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Decatur, IL.
Comments